Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Celldex Therapeutics (CLDX) Prepaid Assets (2016 - 2025)

Celldex Therapeutics has reported Prepaid Assets over the past 16 years, most recently at $14.1 million for Q4 2025.

  • Quarterly results put Prepaid Assets at $14.1 million for Q4 2025, down 33.53% from a year ago — trailing twelve months through Dec 2025 was $14.1 million (down 33.53% YoY), and the annual figure for FY2025 was $14.1 million, down 33.53%.
  • Prepaid Assets for Q4 2025 was $14.1 million at Celldex Therapeutics, down from $21.0 million in the prior quarter.
  • Over the last five years, Prepaid Assets for CLDX hit a ceiling of $22.0 million in Q3 2024 and a floor of $2.4 million in Q4 2021.
  • Median Prepaid Assets over the past 5 years was $10.6 million (2022), compared with a mean of $11.4 million.
  • Biggest five-year swings in Prepaid Assets: skyrocketed 412.78% in 2022 and later plummeted 55.89% in 2023.
  • Celldex Therapeutics' Prepaid Assets stood at $2.4 million in 2021, then skyrocketed by 412.78% to $12.4 million in 2022, then plummeted by 55.89% to $5.5 million in 2023, then soared by 287.38% to $21.2 million in 2024, then tumbled by 33.53% to $14.1 million in 2025.
  • The last three reported values for Prepaid Assets were $14.1 million (Q4 2025), $21.0 million (Q3 2025), and $18.0 million (Q2 2025) per Business Quant data.